Antimicrobial Resistance Diagnostics Market to Reach US$7,620.1 Mn by 2032, Says Persistence Market Research

The antimicrobial resistance (AMR) diagnostics market is witnessing strong growth driven by the urgent need for rapid detection of drug-resistant infections. According to Persistence Market Research, the global market size is projected to grow from US$ 4,830.7 Mn in 2025 to US$ 7,620.1 Mn by 2032, registering a CAGR of 6.7%. This growth is fueled by advancements in molecular diagnostics such as PCR and next-generation sequencing (NGS), as well as increased awareness among healthcare professionals.

The leading segment by technology is Polymerase Chain Reaction (PCR), owing to its rapid turnaround time and high sensitivity in detecting resistance genes. Geographically, North America dominates due to its advanced healthcare infrastructure, robust AMR surveillance systems, and early adoption of cutting-edge diagnostic tools. The region's investment in R&D and public health programs ensures it remains at the forefront of AMR diagnostics adoption.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35211

Market Statistics and Key Growth Drivers

The historical CAGR from 2019 to 2024 stood at 5.2%, showing steady market maturity, but the forecast period is expected to see accelerated expansion due to increasing hospital-acquired infections (HAIs) and multidrug-resistant pathogens like MRSA, CRE, and XDR-TB. Government-backed initiatives, such as WHO's GLASS surveillance program, are actively pushing the adoption of AMR diagnostic solutions.

Market growth is also driven by technological convergence - AI-powered diagnostics, biosensors, and portable point-of-care (PoC) devices are enabling faster, more accurate detection in both hospital and remote settings. The synergy between pharmaceutical firms and diagnostic developers is creating integrated platforms for targeted antimicrobial therapy, further boosting adoption.

Key Highlights from the Report

➤ The AMR diagnostics market is forecast to reach US$ 7,620.1 Mn by 2032, growing at a CAGR of 6.7%.
➤ PCR technology leads due to its speed, sensitivity, and early genetic marker detection capabilities.
➤ Reagents & consumables dominate due to recurring demand in clinical testing workflows.
➤ North America holds the largest market share, followed by Europe and Asia Pacific.
➤ Government AMR surveillance programs like WHO's GLASS are accelerating market penetration.
➤ AI integration and point-of-care testing are emerging as high-growth opportunity areas.

Market Segmentation

Product Insights

The reagents & consumables segment leads the market due to their indispensable role in AMR diagnostic workflows. Unlike capital-intensive diagnostic instruments, consumables like assay kits, culture media, and antimicrobial susceptibility testing (AST) panels require constant replenishment. The rise of molecular testing platforms has further driven the need for specialized reagents. Surveillance programs run by organizations such as WHO and CDC have intensified demand for standardized consumables in AMR testing.

Hospitals and diagnostic laboratories are prioritizing rapid and precise results to support antibiotic stewardship programs. This recurring purchasing pattern for consumables makes them the most lucrative segment, ensuring steady revenue streams for suppliers.

Technology Insights

Polymerase Chain Reaction (PCR) remains the dominant technology in the AMR diagnostics market. Its ability to detect genetic resistance markers directly from patient samples within hours-compared to the 24-72 hours required for traditional culture methods-gives it a critical advantage in clinical decision-making. Multiplex PCR further enhances hospital efficiency by detecting multiple resistance genes in a single test.

Advances such as real-time PCR (qPCR) and digital PCR (dPCR) are improving accuracy, minimizing false results, and expanding clinical applications. PCR's early intervention capability significantly reduces reliance on empirical therapy, improving patient outcomes in multidrug-resistant infection cases.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/antimicrobial-resistance-diagnostics-market.asp

Regional Insights

North America

North America leads the market in 2025, supported by advanced healthcare infrastructure, high diagnostic adoption rates, and strong R&D funding. The U.S. is a pioneer in integrating point-of-care molecular diagnostics for AMR detection, responding quickly to HAIs and resistant pathogens.

Europe

Europe benefits from stringent AMR surveillance mandates, with the EMA and ECDC driving cross-border collaboration. Hospitals are required to conduct routine resistance testing, particularly in high-risk wards, boosting demand for advanced diagnostic solutions.

Asia Pacific

With high infectious disease prevalence and resource-limited settings, Asia Pacific demands affordable, portable AMR detection tools. Low-cost PoC diagnostics and lab-on-a-chip innovations are gaining traction in rural healthcare systems.

Middle East & Africa

Growing partnerships with global biotech companies are enabling technology transfer and local manufacturing. Governments are incentivizing innovation and integrating AI with genomic sequencing for predictive AMR surveillance.

Market Drivers

The primary driver is the rising global antimicrobial resistance crisis, with pathogens such as MRSA, CRE, and XDR-TB reducing treatment effectiveness. The WHO warns AMR could cause 10 million deaths annually by 2050, prompting governments and agencies to invest heavily in rapid diagnostic tools.

Rapid molecular diagnostics, especially PCR and NGS, are gaining ground due to their ability to quickly identify resistant pathogens, enhancing infection control and targeted therapy. National surveillance programs and increased healthcare funding are further strengthening market demand.

Market Restraints

The major restraint is the limited treatment options available once resistance is detected. Despite rapid identification capabilities, the shortage of novel antibiotics limits actionable outcomes from diagnostics. Physicians may hesitate to invest in AMR testing without viable treatment pathways.

Antibiotic stewardship programs, while crucial, often restrict the use of last-resort drugs, reducing the clinical impact of diagnostics in critical care environments. Without parallel drug innovation, diagnostics adoption may face bottlenecks.

Market Opportunities

Opportunities lie in rapid testing innovation and AI integration. Technologies like Sysmex Astrego's under-one-hour UTI test are setting new standards in turnaround times. AI-driven bioinformatics, coupled with digital health platforms, enable smarter antimicrobial stewardship.

Point-of-care testing (POCT) devices and portable biosensors offer immense growth potential in both urban and rural markets. Strategic acquisitions and R&D collaborations between diagnostics and pharma companies will further expand the technological frontier.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35211

Reasons to Buy the Report

✔ Gain insights into a market projected to reach US$ 7,620.1 Mn by 2032.
✔ Understand the technological landscape with detailed PCR, NGS, and biosensor analysis.
✔ Identify lucrative opportunities in point-of-care and AI-powered AMR diagnostics.
✔ Access competitive intelligence on top global and regional players.
✔ Leverage data-backed forecasts for strategic investment planning.

Company Insights

✦ Abbott Laboratories
✦ Accelerated Diagnostics, USA
✦ Alifax
✦ Bio-Rad Laboratories
✦ BioMerieux
✦ Beckman Coulter
✦ Becton, Dickinson and Company
✦ F. Hoffmann-La Roche
✦ Molsid
✦ Thermo Fisher Scientific
✦ Vela Diagnostics
✦ Others

Recent Developments

March 2025 - bioMérieux received FDA 510(k) clearance for its VITEK® COMPACT PRO system for microorganism identification and antibiotic susceptibility testing.

August 2022 - Bio-Rad Laboratories acquired Curiosity Diagnostics from Scope Fluidics for up to $170 million to strengthen rapid molecular diagnostics capabilities.

Conclusion

The antimicrobial resistance diagnostics market is positioned as a critical front-line defense in the global battle against drug-resistant infections. With a projected value of US$ 7,620.1 Mn by 2032, the sector is benefiting from advancements in molecular technologies, AI-driven analytics, and point-of-care innovations that enable faster, more accurate pathogen detection. While challenges such as limited treatment options persist, growing government funding, international AMR surveillance programs, and strategic industry collaborations are fostering a robust growth environment. In this high-stakes landscape, timely and precise diagnostics are not just a market opportunity-they are an essential tool for safeguarding public health and ensuring the sustainability of effective antimicrobial therapies.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.